【癌症】AI精準醫療《Tempus》推出「微量殘存疾病(MRD)」檢測產品，幫助監測早期癌症復發與免疫療法的治療反應
文章出處
Businesswire
原文標題
Tempus Announces the Clinical Launch of its MRD Testing Portfolio
Twitter
https://x.com/aimedadviser/status/1797170317401702402
文章序號
5703
智醫科學－AI醫療技術、應用與市場動態
Copyright ©2024 智醫科學 MEDai.tw All rights reserved.
The content of
this site is intended for healthcare and medical professionals.
